Quickly check methods, data, and figures across full-text papers to verify conclusions.
Press Enter ↵ to review
Fuel Your Discoveries
"The diversity of the phenomena of nature is so great, and the treasures hidden in the heavens so rich, precisely in order that the human mind shall never be lacking in fresh nourishment."
- Johannes Kepler
Quick Explanation
Copied
Concise critical appraisal
Hartmann et al. (2018) present a practical, well-documented mass‑cytometry (CyTOF) reference panel (33 markers) and end‑to‑end workflow for standardized immune monitoring in immunotherapy trials; they validate coverage, reproducibility across centers, and show clinical utility in a small bone‑marrow transplant cohort (n=15 patients, 28 samples) identifying candidate GvHD‑associated signatures
Long Explanation
Visual, evidence‑focused review — Hartmann et al., 2018 (bioRxiv 10.1101/489765)
Visualize first, explain second — key figures recreateable from the paper's reported summary statistics and method descriptions; conclusions strictly traceable to the cited preprint.
Why this paper matters (visual points)
Practical, deployable panel: 33 validated heavy‑metal conjugated antibodies for single‑pass CyTOF profiling covering major lineages and checkpoints ().
Reproducibility checks: PBMC aliquots stained at different centers and compared to flow cytometry showing high correlation (r≈0.96 vs site, r≈0.98 vs flow) ().
Automated analysis compatibility: authors demonstrate tSNE, scaffold maps, FlowSOM clustering and a commercial Astrolabe pipeline — enabling both manual gating and unsupervised discovery ().
Clinical demonstration: applied pipeline to BMT patients (15 patients, 28 PBMC samples), identifying candidate GvHD‑associated reductions in CD27- B cells and naive CD4+ T cells (p~0.004, FDR~0.069) — exploratory and hypothesis‑generating ().
Reproducibility / methods transparency (visual)
These plots are conceptual reconstructions using the correlations reported in the preprint (summary r values). The paper supplies gating strategies, antibody metadata and normalization steps (bead normalization) allowing independent replication by labs with CyTOF instruments .
Critical appraisal — strengths
Practical standardization: provides a near‑complete, ready‑to‑use panel plus instructions for common sample types (PBMC, tumor, lymph node) — valuable for cross‑trial comparability ().
Reproducibility evidence: cross‑site and cross‑platform comparisons (flow vs CyTOF), and PFA‑fixation tests increase confidence in robustness for clinical trials where sample handling varies ().
Flexible analysis: demonstrates both manual gating and unsupervised clustering (FlowSOM/Astrolabe), enabling discovery and confirmatory workflows.
Critical appraisal — limitations, blindspots, and potential biases
Small clinical cohort for claims of disease association: GvHD analysis (n=3 GvHD cases) is underpowered and exploratory (authors report FDR≈0.069); these signals require independent validation in larger, prospective cohorts before clinical use ().
Preprint status (2018): not peer‑reviewed at the posted version — methods are detailed, but some analyses (e.g., statistical modeling choices, batch correction pipelines) would benefit from peer review and code/data release for full reproducibility ().
Automated pipelines and black‑box risks: use of a commercial platform (Astrolabe) is practical but can obscure algorithmic details for some users; independent, open pipelines (FlowSOM, diffcyt) should be provided alongside for transparency (authors used FlowSOM but reliance on a closed platform may limit reproducible auditing).
Marker selection trade‑offs: 33 markers are pragmatic but will miss rare or newly described subsets — authors note ~10 free channels for customization but cell‑type definitions evolve rapidly (single‑cell RNAseq and spectral flow advances since 2018 alter the landscape).
Sensitivity to fixation/processing: some antigens (e.g., CCR7, CD11b) lose signal after fixation — important when comparing fresh vs archived samples; authors measured this but downstream analyses must control for such pre‑analytic variables ().
Potential conflict of interest: one author is co‑founder of Astrolabe Diagnostics (stated in Declaration of Interests) — raises necessity for independent replication without the commercial tool to ensure impartiality.
Conclusions (evidence‑weighted)
The manuscript supplies a high‑value, pragmatic CyTOF panel and an end‑to‑end workflow that meaningfully reduces technical variability and eases cross‑trial comparisons. It is best viewed as an enabling, standardization resource and a source of testable hypotheses (not definitive biomarker validation). The BMT/GvHD findings are promising but preliminary and require larger, independent cohorts with pre‑registered analysis plans and full data/code release for validation ().
Practical recommendations for groups adopting this workflow
Run pilot cross‑site replicates with bead normalization and shared reference PBMCs to quantify batch effects before large trial rollout (authors show such cross‑site concordance but per‑lab calibration still necessary) ().
Prespecify primary immune endpoints and statistical thresholds when using this broad panel (to avoid multiple testing/selection bias); use high‑resolution clustering followed by manual gating confirmation as the authors exemplify.
When possible, share raw FCS/CyTOF files and analysis code (FlowSOM/diffcyt settings, tSNE/UMAP parameters) to enable independent replication and meta‑analysis; the preprint includes methodological descriptions but not a public raw dataset at posting.
Validate any putative clinical signatures (e.g., GvHD signals) in independent cohorts and test sensitivity to sample processing (fixed vs fresh) and instrument platform differences.
Interactive actions
Minimal evidence trail (primary source)
All specific method, validation, and result claims above are drawn directly from the Hartmann et al. preprint:
If you want a full, reproducible reanalysis (re-run clustering, differential abundance testing, and generate publication‑grade figures) from raw FCS/CyTOF files or combined meta‑analysis across cohorts, click to start an AI bioinformatics agent that will iterate on the data and deliver code, figures, and methods.
Feedback:
Updated: March 06, 2026
BGPT Paper Review
Study Novelty
50%
Provides a pragmatic, standardized CyTOF antibody panel and workflow for clinical immunomonitoring — useful and practical but conceptually incremental because high‑parameter cytometry and standardized panels were already emerging; novelty lies in comprehensive validation across centers and explicit clinical pipeline.
Scientific Quality
60%
Methods are detailed and the panel is well justified; strengths include cross‑center comparisons and multiple analysis strategies. Weaknesses: preprint (not peer‑reviewed at posting), limited clinical cohort for biomarker claims (GvHD n=3), partial data/code availability; one author commercial link to Astrolabe requires cautious independent validation.
Study Generality
70%
Panel is broadly applicable to peripheral blood and tissue immune monitoring across immunotherapy trials; extensible channels allow customization, increasing generality for many clinical settings.
Study Usefulness
90%
High practical value: gives labs a validated starting panel, gating strategy, and suggested analytic pipelines that reduce setup time for clinical trials and facilitate cross‑trial comparisons.
Study Reproducibility
60%
Authors include bead normalization, gating strategies, antibody metadata and cross‑site tests improving reproducibility; however, raw data/code were not fully public in the preprint (limiting independent reanalysis). Fixation effects require careful protocol matching across sites.
Explanatory Depth
50%
The paper is an experimental/methods resource rather than a mechanistic study; it documents capabilities and provides pilot clinical observations but does not deeply probe mechanisms of immunotherapy response.
Preparing reproducible CyTOF analysis: iteratively running normalization, FlowSOM clustering, diffcyt differential testing, and generating publication‑ready tSNE/UMAP/cluster heatmaps from FCS files for Hartmann et al. cohorts.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
That single‑timepoint peripheral PD‑L1 or PD‑1 expression alone is sufficient as a predictive biomarker — insufficient because spatial/temporal dynamics and multi‑cell interactions matter.
That automated commercial pipelines produce inherently superior annotations without human QC — risky because algorithmic bias and platform opacity can hide batch or labeling errors.
Quick Explanation
Long Explanation
Top Data Sources
ExportMCP
Analysis Wizard
Hypothesis Graveyard
Potential Experiments
Discussion
Fuel Your Discoveries
Ask a Follow-Up
Key Insight
Keep Exploring
